Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning.
In the last 2 years, regulatory agencies in the UK and the USA have made recommendations and "black box" warnings, regarding the use of atypical antipsychotic drugs in the elderly because of a purported increase in risk of stroke and death in elderly demented patients. These advisories did not address the adverse effects of "typical" (first-generation) antipsychotics. In this article, the author reviews the history of these developments and raises issues that still need to be addressed by the neurologic community.
Friedman
Joseph H
JH
NeuroHealth Parkinson's Disease and Movement Disorders Center, 227 Centerville Rd., Warwick, RI 02886, USA. Joseph_Friedman@Brown.edu
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004348:Drug Labeling; D019317:Evidence-Based Medicine; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced* / Q000517:prevention & control*; D014481:United States
D014150:Antipsychotic Agents